What is drug repurposing?
Drug repurposing — also called drug repositioning, drug re-profiling, or drug re-tasking — is the process of identifying new therapeutic uses for existing, approved, or investigational drugs beyond their original indication. Rather than designing a molecule from scratch, drug repurposing leverages compounds with already-established safety and pharmacokinetic profiles, significantly compressing development timelines and reducing costs.
Excelra supports data-driven drug repurposing through AI/ML analytics, curated SAR data, and scientific informatics — enabling pharma and biotech organizations to systematically identify and validate new indications for shelved or approved compounds.
Drug repurposing vs Drug riscovery — Key differences
While traditional drug discovery involves designing a molecule from the ground up — a process that takes 10–15 years and costs over $2 billion on average — drug repurposing offers a faster, lower-risk alternative by working with compounds that already have extensive safety data.
- Traditional drug discovery: New chemical entity → preclinical → Phase I/II/III trials → approval
- Drug repurposing: Existing compound → new indication hypothesis → targeted trials → approval
- Repurposing typically reduces development timelines by 40–60% and costs significantly less
- Cheminformatics and AI tools play a central role in identifying viable repurposing candidates at scale
| Factor | Drug Repurposing | Traditional Drug Discovery |
|---|---|---|
| Development Time | 3–7 years | 10–15 years |
| Cost | Lower | Very High |
| Safety Data | Already Available | Must Be Generated |
| Risk | Lower | Higher |
| Best Use Cases | Rare diseases, oncology | Novel targets |
How drug repurposing works — 5 Core strategies
A modern drug repurposing strategy typically combines multiple complementary approaches in a data-driven pipeline:
1. Computational drug repurposing
Using AI/ML models and molecular docking, researchers screen existing compounds against new biological targets in silico. Computational drug repurposing eliminates the need for extensive early-stage wet lab work and rapidly narrows the candidate pool — often analyzing millions of compound-target interactions in days.
2. Phenotypic and Network-Based analysis
By mapping drug-target interaction networks and disease pathway data, researchers identify compounds whose mechanisms of action overlap with the biology of a new indication — even when the original target differs. This approach is especially powerful for complex diseases with poorly understood biology.
3. Clinical and Real-World data mining
Mining electronic health records, real-world evidence (RWE), and clinical trial databases reveals unexpected therapeutic effects or off-label signals that suggest new indications for existing compounds.
4. Biomarker-Guided drug repositioning
Integrating biomarker data with compound activity profiles identifies patient subpopulations most likely to respond to a repurposed drug. Biomarker-guided drug repositioning enables precision repurposing strategies with higher clinical trial success rates.
5. Literature and patent mining
Automated text mining and scientific data curation extract drug repurposing signals from published literature, patents, and clinical reports at a scale impossible to achieve manually — connecting observations across millions of documents.
Role of AI and data science in drug repurposing
The convergence of big data, machine learning, and curated scientific databases has transformed drug repurposing AI from a niche strategy into a systematic, scalable discipline.
- Predictive modeling to forecast compound-disease compatibility based on molecular and omics features
- Knowledge graph analysis mapping compound–target–disease relationships across millions of data points
- Multi-omics integration connecting genomics, transcriptomics, and proteomics data with structure-activity relationship (SAR) profiles
- GOSTAR™ SAR data enriching drug repurposing hypotheses with comprehensive bioactivity data
- Automated evidence synthesis combining clinical, preclinical, and real-world data sources
Excelra’s case study on identifying 30 alternate indications for six shelved compounds demonstrates how curated data combined with advanced analytics unlocks new therapeutic value from existing compound portfolios.
Drug repurposing in oncology, rare diseases & infectious conditions
Drug repurposing is particularly impactful where traditional discovery is too slow or too costly. Three areas stand out:
Drug repurposing in oncology
In cancer, precision medicine approaches identify genomic subpopulations where existing drugs show unexpected efficacy. Drug repurposing in oncology is accelerated by biomarker-guided trial design and multi-omics data integration.
Drug repurposing in rare diseases
For orphan and rare diseases, the small patient populations make de novo drug development economically unviable. Drug repurposing in rare diseases provides a viable route to approved therapies by leveraging existing safety data and compressing clinical development.
Drug repurposing in infectious diseases
Drug repurposing has been a primary rapid-response strategy in pandemic settings, where the urgency of deployment makes de novo discovery impractical and established safety profiles are critical.
Excelra’s Data-Driven drug repurposing approach
Excelra’s data-driven drug repurposing services combine curated scientific data, AI analytics, and deep domain expertise to help organizations unlock value from existing compound portfolios.
- GOSTAR™ SAR database — comprehensive compound-activity data powering drug repurposing hypotheses
- Cheminformatics — molecular profiling, similarity analysis, and target identification for repurposing
- AI/ML analytics — predictive models for compound-indication matching and patient stratification
- Scientific data curation — curated datasets from literature, clinical data, and public repositories
- HEOR & Real World Evidence — real-world signals informing repurposing feasibility and indication selection
Conclusion
Drug repurposing — and specifically computational drug repurposing powered by AI and curated data — is one of the most efficient strategies available for accelerating the delivery of new therapies to patients. By combining AI-driven drug repositioning tools, multi-omics insights, and SAR-rich databases, organizations can systematically identify high-confidence repurposing candidates and reduce time-to-approval. Explore how Excelra’s drug repurposing solutions can help unlock hidden therapeutic value in your existing portfolio.
What is drug repurposing in simple terms?
Drug repurposing means finding a new medical use for a drug originally developed for a different condition. It saves time and money because the drug’s safety in humans is already established, allowing development to skip or shorten Phase I trials.
What is the difference between drug repurposing and drug repositioning?
Drug repurposing and drug repositioning are used interchangeably — both refer to identifying new indications for existing compounds. Some researchers apply repurposing to approved drugs and repositioning to investigational compounds, but there is no universally agreed distinction between the two terms.
What is computational drug repurposing?
Computational drug repurposing uses in silico methods — including AI/ML models, molecular docking, network analysis, and virtual screening — to identify new therapeutic uses for existing compounds. It allows researchers to evaluate millions of compound-disease combinations rapidly without requiring laboratory experiments at the screening stage.
How does AI help in drug repurposing?
AI and machine learning analyze datasets including compound libraries, genomics data, clinical records, and scientific literature to identify previously unrecognized connections between existing drugs and new disease targets. Drug repurposing AI dramatically speeds up hypothesis generation and increases the confidence of candidate selection.
Can Excelra help identify repurposing candidates for my compound portfolio?
Yes. Excelra’s data-driven drug repurposing services combine curated SAR data, AI analytics, HEOR insights, and multi-omics integration to identify and prioritize repurposing opportunities. Contact the team to discuss your specific portfolio.
